EVOLUS INC (EOLS) Stock Fundamental Analysis
USA - NASDAQ:EOLS - US30052C1071 - Common Stock
7.315 USD
+0.33 (+4.65%)
We assign a fundamental rating of 3 out of 10 to EOLS. EOLS was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of EOLS have multiple concerns. EOLS is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year EOLS has reported negative net income.
EOLS had a negative operating cash flow in the past year.
EOLS had negative earnings in each of the past 5 years.
In the past 5 years EOLS always reported negative operating cash flow.
1.2 Ratios
EOLS has a Return On Assets (-27.10%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.1% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EOLS has a better Gross Margin (66.63%) than 74.87% of its industry peers.
EOLS's Gross Margin has declined in the last couple of years.
EOLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
2. Health
2.1 Basic Checks
EOLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EOLS has been increased compared to 1 year ago.
EOLS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for EOLS has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -1.80, we must say that EOLS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.80, EOLS is in line with its industry, outperforming 46.60% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.8 |
ROIC/WACCN/A
WACC10.26%
2.3 Liquidity
EOLS has a Current Ratio of 2.27. This indicates that EOLS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.27, EOLS is in line with its industry, outperforming 40.84% of the companies in the same industry.
EOLS has a Quick Ratio of 1.86. This is a normal value and indicates that EOLS is financially healthy and should not expect problems in meeting its short term obligations.
EOLS has a Quick ratio of 1.86. This is comparable to the rest of the industry: EOLS outperforms 42.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.86 |
3. Growth
3.1 Past
EOLS shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.76%.
The Revenue has grown by 31.76% in the past year. This is a very strong growth!
EOLS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 50.14% yearly.
EPS 1Y (TTM)-9.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
Revenue 1Y (TTM)31.76%
Revenue growth 3Y38.74%
Revenue growth 5Y50.14%
Sales Q2Q%12.9%
3.2 Future
The Earnings Per Share is expected to grow by 62.01% on average over the next years. This is a very strong growth
Based on estimates for the next years, EOLS will show a very strong growth in Revenue. The Revenue will grow by 21.42% on average per year.
EPS Next Y-91.76%
EPS Next 2Y82.04%
EPS Next 3Y81.42%
EPS Next 5Y62.01%
Revenue Next Year11.18%
Revenue Next 2Y18.76%
Revenue Next 3Y22.78%
Revenue Next 5Y21.42%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
EOLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 22.27 indicates a rather expensive valuation of EOLS.
76.44% of the companies in the same industry are more expensive than EOLS, based on the Price/Forward Earnings ratio.
EOLS's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 33.72.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 22.27 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
EOLS's earnings are expected to grow with 81.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y82.04%
EPS Next 3Y81.42%
5. Dividend
5.1 Amount
EOLS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:EOLS (11/12/2025, 3:36:08 PM)
7.315
+0.33 (+4.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners83.43%
Inst Owner Change-1.17%
Ins Owners7.31%
Ins Owner Change0.18%
Market Cap473.21M
Revenue(TTM)266.27M
Net Income(TTM)-61.99M
Analysts84.62
Price Target19.21 (162.61%)
Short Float %25.4%
Short Ratio14.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-54.87%
Min EPS beat(2)-108.79%
Max EPS beat(2)-0.95%
EPS beat(4)1
Avg EPS beat(4)-41.86%
Min EPS beat(4)-108.79%
Max EPS beat(4)3.2%
EPS beat(8)4
Avg EPS beat(8)-24.08%
EPS beat(12)8
Avg EPS beat(12)-14.96%
EPS beat(16)10
Avg EPS beat(16)-10.12%
Revenue beat(2)0
Avg Revenue beat(2)-12.02%
Min Revenue beat(2)-17.08%
Max Revenue beat(2)-6.96%
Revenue beat(4)0
Avg Revenue beat(4)-7.33%
Min Revenue beat(4)-17.08%
Max Revenue beat(4)-1.09%
Revenue beat(8)2
Avg Revenue beat(8)-2.45%
Revenue beat(12)4
Avg Revenue beat(12)-2.38%
Revenue beat(16)6
Avg Revenue beat(16)-1.12%
PT rev (1m)-2.35%
PT rev (3m)-18.12%
EPS NQ rev (1m)-9.52%
EPS NQ rev (3m)-392.86%
EPS NY rev (1m)2.59%
EPS NY rev (3m)-279.03%
Revenue NQ rev (1m)-0.46%
Revenue NQ rev (3m)-20.2%
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)-15.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 22.27 | ||
| P/S | 1.7 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.45
EYN/A
EPS(NY)0.33
Fwd EY4.49%
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS4.3
BVpS-0.29
TBVpS-1.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.1% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.63% | ||
| FCFM | N/A |
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
F-Score2
Asset Turnover1.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 119.75% | ||
| Cap/Sales | 2.48% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.86 | ||
| Altman-Z | -1.8 |
F-Score2
WACC10.26%
ROIC/WACCN/A
Cap/Depr(3y)67.26%
Cap/Depr(5y)52.74%
Cap/Sales(3y)1.53%
Cap/Sales(5y)2.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
EPS Next Y-91.76%
EPS Next 2Y82.04%
EPS Next 3Y81.42%
EPS Next 5Y62.01%
Revenue 1Y (TTM)31.76%
Revenue growth 3Y38.74%
Revenue growth 5Y50.14%
Sales Q2Q%12.9%
Revenue Next Year11.18%
Revenue Next 2Y18.76%
Revenue Next 3Y22.78%
Revenue Next 5Y21.42%
EBIT growth 1Y-35.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-927.53%
EBIT Next 3Y291.62%
EBIT Next 5Y182.73%
FCF growth 1Y23.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.78%
OCF growth 3YN/A
OCF growth 5YN/A
EVOLUS INC / EOLS FAQ
What is the ChartMill fundamental rating of EVOLUS INC (EOLS) stock?
ChartMill assigns a fundamental rating of 3 / 10 to EOLS.
Can you provide the valuation status for EVOLUS INC?
ChartMill assigns a valuation rating of 2 / 10 to EVOLUS INC (EOLS). This can be considered as Overvalued.
Can you provide the profitability details for EVOLUS INC?
EVOLUS INC (EOLS) has a profitability rating of 1 / 10.
How financially healthy is EVOLUS INC?
The financial health rating of EVOLUS INC (EOLS) is 3 / 10.
What is the expected EPS growth for EVOLUS INC (EOLS) stock?
The Earnings per Share (EPS) of EVOLUS INC (EOLS) is expected to decline by -91.76% in the next year.